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Summary--Adult rats were treated with ethane dimethane sulphonate (EDS), n agent that 
destroys Leydig cells. Within 5 days after EDS treatment, the levels of testosterone (T) in the 
circulation and in the testis were decreased to very low values, which makes it possible to 
manipulate the testicular T concentration through administration of exogenous T. Spermato- 
genesis was not markedly affected within 5 days after EDS treatment, also n t in the absence 
of T administration. 
In testes of EDS-treated rats, the androgen receptor mRNA (ARmRNA) level remained 
unaltered for 5 days. In ventral prostate, however, this treatment caused a pronounced 
upregulation of the level of ARmRNA, which could be counteracted by implantation of 
silastic T implants immediately fterEDS treatment. 
In EDS-treated rats carrying a T implant and in untreated rats, the same number of specific 
[3H]R1881 binding sites was observed using a totaltestis nuclear fraction (Scatchard analysis). 
In testes from EDS-treated rats without T implants, androgen receptors (AR) did not 
fractionate into the nuclear fraction; however, th  total testicular AR content in these animals 
(measured by nuclear [3H]R1881 binding after receptor transformation through injection of 
a high dose of T, 2 h before killing the rats) remained unaltered. 
Immunoprecipitation and Western blotting using anti N-terminal antibodies seemed to 
indicate that the total testicular amount of AR protein in the EDS-treated rats was very low 
as compared to that in EDS-treated rats carrying T implants and in untreated rats. Even after 
receptor etransformation (by injection of a high dose of T) the receptors were not 
quantitatively detected by immunoprecipitation and Western blotting. This may point to a 
structural modification of the AR that occurs in the prolonged absence of androgens. 
INTRODUCTION 
During fetal and postnatal life, androgens play 
a crucial role in male development. The present 
work relates to the role of androgens in the 
initiation and maintenance of spermatogene- 
sis [1]. In different androgen dependent tissues, 
testosterone and dihydrotestosterone int ract 
with the androgen receptor and regulate a num- 
ber of different processes. It is generally believed 
that upon androgen binding the receptor is 
transformed to a DNA binding form that regu- 
lates the expression of androgen-dependent 
genes [2, 3]. In ventral prostate, a well studied 
androgen-dependent tissue, the androgen recep- 
tor mRNA and protein levels are both regulated 
by androgens. The number of androgen recep- 
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tors is decreased in the absence of androgens, 
while under the same experimental conditions 
the amount of androgen receptor mRNA is 
increased [4, 5]. From experiments using cul- 
tured cells of different origin, it has been con- 
cluded that the androgen receptor protein is 
unstable in the absence of androgens [6, 7]. 
The regulation of the androgen receptor 
mRNA and protein in the testis in vivo is not 
extensively documented. Using isolated cells 
from the testis, however, more data have 
become available. Buzek and Sanborn [8] have 
described an increase in androgen receptor 
number during postnatal testis development, 
in cultured Sertoli cells and freshly isolated 
Leydig cells but not in cultured peritubular 
myoid cells. In cultured Sertoli cells from imma- 
ture rats, Verhoeven and Cailleau[9] have 
shown an additive stimulatory effect of FSH 
and testosterone on the androgen receptor 
protein ([3H]Mibolerone binding). Androgen 
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Table 1. [3H]RI881 binding data and post mortem hormonal parameters from animals treated with EDS and substituted 
with testosterone and/or FSH 
Testis weight FSH Serum T Testicular T Nuclear AR 
(mg) (ng/ml) (nmol/l) (rig/g) (%) 
Control 1583 _+ 95 8.1 _+ 1.8 7.4 _+ 6.0 47.6 S 33.0 100 
Control + T-pulse 1517 _+ 73 6.6 + 7.2 470.0 + 110.0 115.3 + 27.6 104 __. 21 
EDS 1432 + 46 13.3 + 3.7 <0.3 2.2 + 2.5 8 + 7 
EDS + T-pulse 1413_+54 10.1_+1.7 555.0+87.0 74.4-+27.4 97-+17 
EDS+T 1502-+41 2.3+0.6 45.3-+8.1 10.4-+ 1.0 81 -+ 11 
EDS + T + T-pulse 1563-+64 2.6_+0.9 409.0_+ 163.0 76.0_+ 12.6 113+24 
EDS + T+ FSH 1555_+ 171 8.7_+0.9 38.4_+8.1 11.1 _+ 1.3 132_+35 
EDS + T + FSH + T-pulse 1667_+109 7.5__.1.0 510.0_+160.0 99.3_+18.7 139_+13 
EDS + FSH 1441 _+ 97 19.3 .%+ 2.7 0.4 _+ 0.4 0.8 _+ 1.3 <5 
EDS + FSH + T-pulse 1402 _+ 62 17.2 _ 2.4 449.0 __. 77.2 89.0 _+ 17.3 78 _ 9 
T-pulse = testosterone injection (10 mg) 2 h prior to killing; EDS = killed 5 days after EDS treatment; T = substitution 
with testosterone for 5 days (15 cm silastic implants); FSH = substitution with FSH for 5 days (2 x 5 IU injected 
per day). Results represent mean + SD of 5 rats in each group. The nuclear AR was estimated using 3 different 
preparations of testicular nuclei. 
receptor mRNA expression i  these cells, how- 
ever, was stimulated only by FSH but not by 
testosterone [10]. 
In the present study, ethane dimethane 
sulphonate (EDS; an alkylating agent hat de- 
stroys Leydig cells in rats through an unknown 
mechanism) was used to deprive the testes of 
adult rats of testosterone within 3 days [11]. EDS 
treatment was followed by administration of
either no hormone, or testosterone and/or FSH 
for 5 days. Data on androgen receptor mRNA 
expression were obtained using Northern and 
dot-blot analysis. The androgen receptor protein 
level was estimated by [3H]R1881 binding, and 
by immunoprecipitation and Western blotting. 
THE ANDROGEN RECEPTOR mRNA 
Treatment of adult rats with EDS resulted in 
an undetectable level of serum testosterone and 
a very low level of testicular testosterone, but 
did not lead to a noticeable impairment of 
spermatogenesis and did not affect estis weight 
(Table 1). 
Using Northern blot analysis, 10kb and 
4-5kb bands were detected by hybridizing 
to the cDNA (Fig. 1). The 10kb band is 
considered as the intact androgen receptor 
mRNA, with a length that is in agreement with 
the length of the cloned cDNAs and the 
genomic organization of the androgen recep- 
tor [12, 13]. The 4-5 kb band is thought o rep- 
resent a cross-hybridization artifact of the 
labeled probe with ribosomal RNA [5]. In the 
present experiments, however, it is shown that 
spleen total RNA, which contains very little 
androgen receptor mRNA, did not cross-hy- 
bridize with the cDNA probe, indicating that 
the 4-5 kb band does not represent ribosomal 
RNA. Furthermore, when ventral prostate 
RNA was incubated at room temperature for 
48 h, the 10 kb mRNA was broken down to a 
4-5 kb band. It is concluded that the 4-5 kb 
band is a breakdown product of the 10kb 
androgen receptor mRNA (Fig. 1). This 
validates the use of dot-blot analysis of total 
RNA to estimate androgen receptor mRNA 
expression. 
,~- to to b. v- 
Fig. I. Nor thern  analysis o f  total  RNA extracted f rom spleen and  ventral  prostate.  Different amounts  
o f  spleen RNA were appl ied per lane (35, 50, 70 and  105 #g RNA) .  The ventral  prostate  RNA (35 #g)  
was kept for 0, 2, 6, 24, 36 and  48 h at room temperature.  
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REGULATION OF ANDROGEN RECEPTOR 
mRNA EXPRESSION 
An increased level of androgen receptor 
mRNA was observed in the ventral prostate of 
the EDS-treated rats (Fig. 2a). This indicates 
that treatment with EDS without substitution of 
testosterone, has an effect comparable to that 
of castration on androgen receptor mRNA 
expression in the ventral prostate [13]. 
Under the present experimental conditions, no 
testosterone-dependent change in androgen re- 
ceptor mRNA expression in the testis was ob- 
served (Fig. 2b). It is true that following EDS 
treatment he testicular testosterone concen- 
tration does not drop as fast as the serum 
testosterone concentration, and it cannot be 
excluded therefore that the testes were deprived 
of testosterone only for a relatively short time 
period during the 5 days following the EDS treat- 
ment. To study this point, EDS-treated rats were 
killed 7 days after treatment, but even then no 
change in testicular androgen receptor mRNA 
expression was detected. Furthermore, seminif- 
erous tubules were isolated 5 days after EDS 
treatment and incubated for 20 h in the presence 
or absence of testosterone. In these tubules, down 
regulation of the androgen receptor mRNA 
expression by testosterone was not observed. 
ANDROGEN BINDING 
For estimation of the specific [3H]R1881 bind- 
ing sites (Scatchard analysis), a nuclear fraction 
was isolated from total testis. The procedure for 
isolation of the nuclear fraction included tissue 
fractionation under liquid nitrogen and the use 
of buffers containing a high concentration of 
sucrose [14], in order to prevent loss of nuclear 
androgen receptor. The total amount of andro- 
gen receptors in the testis estimated using this 
method, was in agreement with published 
results [8]. 
Treatment of EDS-treated rats with silastic 
testosterone implants for 5 days resulted in a 
testicular testosterone level at approximately 
20% of the control value (Table 1). The 
[3H]R1881 binding level in the testicular nuclear 
fraction of these testosterone substituted ani- 
mals, however, remained unaltered as compared 
to control animals (Table 1, group 5). In testes 
deprived of testosterone, very low binding of 
[3H]R1881 in the nuclear fraction was observed 
(Table 1, groups 3 and 9). This is most likely 
not explained by a cytoplasmic localization of 
the unoccupied receptor. Recently Husmann 
et al. [15] reported nuclear localization of the 
androgen receptor in the presence as well as in 
the absence of ligand. In the present study 
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Fig. 2. Dot blot analysis of total RNA extracted from ventral prostate (A) and testis (B). Tp = testosterone 
injection (10 mg) 2 h prior to killing; EDS = killed 5 days after EDS treatment; T = substitution with 
testosterone for 5 days (15cm silastic implants); FSH = substitution with FSH for 5 days (2 x 5 IU 
injected per day). RNA was applied to the filter in two-fold dilution series and analyzed using a human 
androgen receptor cDNA probe. 
346 LEEN J. BLOK et al. 
untransformed receptor molecules may have 
been lost from the nucleus upon cell fraction- 
ation, despite the precautions. Therefore, rats 
in the different experimental groups were 
treated with a very high dose of testosterone 
(10 mg) 2 h prior to killing (T-pulse), to retrans- 
form androgen receptors to a tight nuclear 
binding form. The results show that also in the 
EDS-treated rats that did not carry a T implant 
(groups 3 and 9), testicular AR were still present 
and became retransformed to a tight nuclear 
binding form upon T-pulse treatment (groups 4 
and 10). 
It has been reported that testosterone exerts 
an effect on the stability of the androgen recep- 
tor in various cell culture systems [6, 7]. The 
untransformed receptor may undergo a high 
turnover, which might be markedly reduced 
upon ligand binding and conversion of the 
receptor to a tight nuclear binding form. The 
present results on [3H]R1881 binding, however, 
seem to indicate that the androgen receptor in 
the testis is quite stable in the absence of 
testosterone. 
IMMUNOPRECIPITATION OF THE 
ANDROGEN RECEPTOR 
Immunoprecipitation a d Western blotting 
was performed to confirm the maintenance of 
the androgen receptor protein  testosterone 
deprived testis. Using monoclonal and poly- 
clonal antibodies against the N-terminal 
domain of the human androgen receptor [18], a 
116 kDa band was observed (Fig. 3). 
In animals treated with EDS and receiving 
testosterone implants (groups 5-8), the same 
level of immunoprecipitable androgen receptor 
was observed as in control animals. However, 
animals treated with EDS but not receiving 
testosterone implants (groups 3, 4, 9 and 10), 
had very low levels of immunoprecipitable an- 
drogen receptor. It should be noted that the 
Western blots represent immunoprecipitation 
from total testis homogenates, o that loss of 
androgen receptor from the nuclear fraction 
does not have an influence on the outcome of 
the experiments. 
The intriguing discrepancy between the 
results derived from the ligand binding and 
kD 
c~ 
+ o.  
I I 
~ O_ i, I I 
+ c, + + + 03 ta3 
+ + 4- + + + + 
o o t'~ ~ ~ E3 E3 r~ 0 
~.~ ~D w Ld W W W W W W 
66- -  
45 
Fig. 3. Western blot analysis of the androgen receptor immunoprecipitated from testis lysates. 
Tp = testosterone injection (10mg) 2h prior to killing; EDS = killed 5 days after EDS treatment; 
T = substitution with testosterone for 5 days (15 cm silastic implants); FSH = substitution with FSH for 
5 days (2 x 5 IU injected per day). 
Regulation of the 
immunoprecipitat ion experiments i  not readily 
explained. Apparently, the antibodies poorly 
bind to the androgen receptors from testoster- 
one depleted testis (also not after retransforma- 
tion, 2h  after injection of a high dose of 
testosterone). This may point to a permanent 
structural modification of the untransformed 
androgen receptor that occurs in the prolonged 
absence of testosterone. Possibly, the untrans- 
formed receptor undergoes proteolytic leavage, 
resulting in loss of the N-terminal  region which 
is recognized by the monoclonal  ant ibody used, 
without a concomitant change in the [3H]R1881 
binding. On the other hand, immunoprecipita- 
tion of the androgen receptor from the andro- 
gen depleted testis may be inhibited through 
interaction of the androgen receptor with 
another protein. The exact nature of the puta- 
tive modification of the androgen receptor will 
be subject to further investigation. 
ROLE OF FSH AND THE TESTICULAR 
TESTOSTERONE CONCENTRATION 
The present results do not show an effect of 
FSH treatment on testicular androgen receptor 
mRNA and protein levels. This can be ex- 
plained, because the present study concerns 
total testicular androgen receptors in adult ani- 
mals, rather than androgen receptors in cultured 
Sertoli cells from immature rats [9, 10]. 
In the literature, there is an ongoing debate 
about the testicular testosterone concentration 
that is needed to maintain spermatogene- 
sis [16, 17]. An approach based on the present 
study (EDS-treated rats substituted with differ- 
ent lengths of testosterone implants for 5 days, 
starting immediately after EDS treatment) may 
provide a model to try to answer the question at 
what testosterone concentration the testicular 
androgen receptor becomes transformed to the 
tight nuclear binding form. The present results 
indicate that approximately 20% of the control 
testicular androgen concentration may be suffi- 
cient to promote complete transformation f the 
androgen receptor. 
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